Tagged with BI

Canada “If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career path, the company’s dual focus on medicinal and recreational cannabis, and how Canada will always remain the core center of…

Portugal Paulo Lilaia, president of the board of APOGEN and CEO of Generis, highlights the need for generics in the healthcare system and the government’s approach to their implementation. He also discusses the introduction of biosimilars into the Portuguese healthcare system and the cost-saving effect this has for patients and companies,…

Malta Paul Apap Bologna, managing director at Associated Drug Company (ADC), introduces his family company, focused on distributing high-quality innovative solutions to Maltese patients, and evokes the key opportunities that the medicinal cannabis segment can represent for Malta and the industry. Established in 1930, Associated Drug Company (ADC) has a long…

Malta Prof. Claude A. Farrugia of the Malta Chamber of Commerce, Enterprise and Industry documents the main trends in the manufacturing industry of Malta and discusses the island’s strengths in discovering new niches and exploiting opportunities as they present themselves. Farrugia also touches on the development of a biotech industry on…

Spain Ion Arocena, CEO of ASEBIO, Spain’s biotech association, discusses the significant efforts that Spain has made in turning cutting-edge research into successful companies and products and provides an insight into the level of collaboration and interaction between all stakeholders across the whole healthcare ecosystem. Can you provide us a with…

Canada With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO Neil Closner also highlights MedReleaf’s important efforts in conducting R&D and clinical studies in order to present practitioners with relevant…

Canada Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering from rare diseases, while emphasizing the importance of an adequate rare disease framework to streamline this process in the future.…

India Bharat V. Daftary, chairman and MD of Bharat Serums & Vaccines (BSV), a biopharmaceutical company with R&D units in USA, Germany & India and with a presence in over 76 countries, provides insights into the biotech landscape in India and its expectations for the fertility and women’s health markets. He…

UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.     Most likely, the UK is the best environment for putting forward trials that are properly…

Canada Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer Biomet positions itself as a true partner in driving efficiency in the Canadian healthcare system. 2017 was an eventful year…

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

India The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is accounted for by contract research organisations (CROs). Within India, the contract research market is scheduled to grow from around USD one billion in 2016 to USD 1.97 billion by 2023 according…